



Artery Research

ISSN (Online): 1876-4401

ISSN (Print): 1872-9312

Journal Home Page: <https://www.atlantis-press.com/journals/artres>

***Porphyromonas gingivalis* vesicles reduce MDA-LDL levels and aortic wall thickness in high fat diet induced atherosclerosis rats**

Aditya Indra Mahendra, Jonny Karunia Fajar, Harapan Harapan, Teuku Heriansyah, Sumarno Reto Prawiro, Edi Widjajanto, Mohammad Saifur Rohman, Karyono Mintaroem, Budi Susetio Pikir, Yash Prashar

To cite this article: Aditya Indra Mahendra, Jonny Karunia Fajar, Harapan Harapan, Teuku Heriansyah, Sumarno Reto Prawiro, Edi Widjajanto, Mohammad Saifur Rohman, Karyono Mintaroem, Budi Susetio Pikir, Yash Prashar (2018) *Porphyromonas gingivalis* vesicles reduce MDA-LDL levels and aortic wall thickness in high fat diet induced atherosclerosis rats, Artery Research 23:C, 20–27, DOI:

<https://doi.org/10.1016/j.artres.2018.05.008>

To link to this article: <https://doi.org/10.1016/j.artres.2018.05.008>

Published online: 3 December 2019



Porphyromonas gingivalis vesicles reduce MDA-LDL levels and aortic wall thickness in high fat diet induced atherosclerosis rats

Aditya Indra Mahendra ^{a,b,*}, Jonny Karunia Fajar ^c,
Harapan Harapan ^c, Teuku Heriansyah ^{d,**},
Sumarno Reto Prawiro ^e, Edi Widjajanto ^f,
Mohammad Saifur Rohman ^{b,g}, Karyono Mintaroem ^h,
Budi Susetio Pikir ^{i,***}, Yash Prashar ^j

^a Faculty of Medicine, Brawijaya University, Malang, 65145, Indonesia

^b Brawijaya Cardiovascular Research Center, Brawijaya University, Malang, 65145, Indonesia

^c Medical Research Unit, School of Medicine, Syiah Kuala University, Banda Aceh, 23111, Indonesia

^d Department of Cardiology and Vascular Medicine, School of Medicine, Syiah Kuala University, Banda Aceh, 23111, Indonesia

^e Department of Microbiology, Faculty of Medicine, Brawijaya University, Malang, 65145, Indonesia

^f Department of Clinical Pathology, Faculty of Medicine, Brawijaya University, Malang, 65145, Indonesia

^g Department of Cardiology and Vascular Medicine, Faculty of Medicine, Brawijaya University, Malang, 65145, Indonesia

^h Department of Anatomic Pathology, Faculty of Medicine, Brawijaya University, Malang, 65145, Indonesia

ⁱ Department of Cardiology and Vascular Medicine, Faculty of Medicine, Airlangga University, Surabaya, 60286, Indonesia

^j Department of Pharmacology, Rayat Institute of Pharmacy, Distt. S.B.S Nagar, Railmajra, Punjab, 144533, India

Received 22 April 2018; received in revised form 9 May 2018; accepted 16 May 2018

Available online 1 June 2018

KEYWORDS

Atherosclerosis;
Vaccines;

Abstract *Background:* Recently, atherosclerosis-associated disease has been reported simultaneously increased. Whereas, to date, no atherosclerosis vaccine is available. Since the epitope mimicry between malondialdehyde low-density lipoprotein (MDA-LDL) and arginine

* Corresponding author. Faculty of Medicine, Brawijaya University, Malang, 65145, Indonesia.

** Corresponding author.

*** Corresponding author.

E-mail addresses: adityaindr@gmail.com (A.I. Mahendra), teuku_hery@unsyiah.ac.id (T. Heriansyah), bsp49@fk.unair.ac.id (B.S. Pikir).

MDA-LDL;
Vesicles;
Porphyromonas
gingivalis

specific epitope gingipain (Rgp) on the *Porphyromonas gingivalis* vesicles has been reported, it raises an opportunity to employ the potency of *P. gingivalis* as an atherosclerosis vaccine.

Objective: To evaluate the potency of *P. gingivalis* vesicles to prevent atherosclerosis, by assessing MDA-LDL level, visceral fat, body weight, and aortic wall thickness, in rats model.

Methods: Five groups of rats (n = 10 per group), three treatment groups, one positive and negative control group were assigned and adapted with high fat diet for 8 weeks. The treatment groups were injected with *P. gingivalis* vesicles with and without adjuvant with four booster doses. The level of MDA-LDL serum, visceral fat, body weight, and aortic wall thickness were measured in the end of the course.

Results: Our present study found that decreased in MDA-LDL levels ($p = 0.037$) and aortic wall thickness ($p = 0.016$) were observed in rats treated with vesicles and adjuvants, but not with vesicles or adjuvants only, compared to negative control. Moreover, MDA-LDL levels in rats immunized with vesicles and adjuvants were significantly lower than healthy rats. However, body weight ($p = 0.329$ and visceral fat ($p = 0.789$) were not significantly different in all treatment groups compared to control.

Conclusions: Immunization with *P. gingivalis* vesicles and adjuvants significantly reduces MDA-LDL level and aortic wall thickness in rats model.

© 2018 Association for Research into Arterial Structure and Physiology. Published by Elsevier B.V. All rights reserved.

Introduction

Atherosclerosis, narrowing of the arteries caused by plaque deposits, contributes to a high number of morbidity and mortality of cardiovascular and cerebrovascular diseases globally.^{1,2} In 2015, there were 17.7 million deaths associated with cardiovascular diseases and representing 31% of all global deaths.³ Although atherosclerosis management has been established,⁴ the mortality rates due to atherosclerosis-associated diseases have increased in the last two decades.⁵ This because the management of atherosclerosis is a complex, involving various aspects.⁶ Therefore, management with a prevention approach such as vaccination is likely to bring better outcome. Several atherosclerosis vaccines have been studied and each of them has a different target site antigen, such as malondialdehyde low-density lipoprotein (MDA-LDL),^{7–12} native LDL or copper oxidized-LDL,^{13–15} and p210.^{16–19} Of these antigens, MDA-LDL is the most widely studied. MDA-LDL is the most important oxidized LDL (ox-LDL) and considered more atherogenic than LDL.²⁰ A study found that the induction of antibodies against MDA-LDL was associated with reduced atherosclerotic lesion formation and lower serum cholesterol level.¹⁰

Recently, the correlation between infectious pathogens and the diseases has been proposed to elicit the potency of vaccination, for example: *Streptococcus pneumoniae*²¹ and *Salmonella typhimurium*²² were shown to have an effect on the decreased risk of atherosclerosis; influenza vaccination were found to be associated with reduced risk of stroke,²³ and pneumococcal polysaccharide vaccine had been disclosed beneficial for reduction of acute coronary syndrome risk.²⁴ Periodontitis is an inflammation of the periodontal and supporting structures of the teeth, associated with polymicrobial infections including *Porphyromonas gingivalis*, one of the major contributors of this disease. Scientific evidence revealed that periodontopathogens such as *P. gingivalis* during periodontitis have a pivotal role in

inducing in the development of atherosclerosis.²⁵ This correlation is probably due to the structure mimicry between MDA-LDL and arginine specific epitope gingipain (Rgp) on the vesicles of *P. gingivalis*, structures with high immunogenicity.²⁶ Theoretically, two high immunogenic properties having similar fragment size have the potency to generate cross-immunity.²⁷ Based on this, this study sought to evaluate the potency of *P. gingivalis* vesicles to be an atherosclerosis vaccine in rats model assessed by MDA-LDL, visceral fat, body weight, and aortic wall thickness. The results of this study provide a primary data the potency of *P. gingivalis* vesicles as atherosclerosis vaccine candidate.

Methods

Animal and *P. gingivalis* outer membrane vesicles

Male albino wistar rats at eight weeks of age were purchased from Physiology Laboratorium, Brawijaya University. Ten of them were randomly assigned into each study group. All animal protocols in this study were approved by the Ethical Committee of Brawijaya University, Malang, Indonesia and were carried out in strict accordance with the Indonesian law and guidelines on the use of experimental animals. The study was conducted in animal facilities at Biomedical Laboratory, Brawijaya University.

P. gingivalis strain (ATCC[®] 33277[™]), kindly provided by Supriyono Hasan from Microbiology Laboratory, Faculty of Dentistry, Airlangga University, was used. The outer membrane vesicles of *P. gingivalis* vesicles were isolated according to previous study.²⁸ Briefly, after separating from the culture media, the bacterial cells were mixed with 40% ammonium sulfate for two hours and centrifuged at 20,000 g for 40 min. The pellet was suspended with Tris buffer (50 mM, pH 9.5) containing 0.5 mM dithiothreitol (DTT) (ThermoFisher, MA, USA) and was dialyzed overnight.

The vesicles were then collected by centrifugation (27,000 g for 40 min) and resuspended in 10 ml of Tris buffer. Finally, the suspension was re-centrifuged at 27,000 g for 40 min and the vesicles were resuspended in 1.5 ml of Tris buffer (pH 7.2) and stored at 40 °C for immunization.

High fat diet

High fat diet (HFD) was adapted from previous study with some modifications.²⁹ Briefly, the animals were fed with HFD consisted of 4% cholesterol, 1% cholic acid, 0.5% thio-uracil, 10% pork oil, and 5% duck egg yolk. The diet was provided *ad libitum*. HFD was given at 10 weeks of age in the negative control group and three treatment groups.

P. gingivalis vesicle challenge

Male wistar rats were divided into five groups: three intervention groups and two control groups. The first intervention group (T1) was given a HFD and injected intraperitoneally with 100 µl *P. gingivalis* vesicles and adjuvants (antigen to adjuvants ratio was 1:1). The second group (T2), was at a HFD and injected with 100 µl vesicles only while the third group (T3) was at a HFD and injected with adjuvants only. A group of rats (PC) were injected with aquabidest while another group (NC) were given HFD only. A booster dose of *P. gingivalis* vesicles (100 µl) was administered two weeks following the initial dose and repeated until four times in fortnight interval. During initial and booster dose, complete (CFA) and incomplete Freund adjuvants (IFA) were used, respectively. All rats were euthanized after eight weeks on HFD.¹⁰

MDA-LDL measurement

MDA-LDL serum levels were measured using ELISA as described previously with some modifications.³⁰ ELISA plates were coated with the capture antibody for MDA-LDL (Abcam, San Francisco, USA) at 10 µg/ml concentration in bicarbonate buffer (pH 9.6) then the plates were incubated at 4 °C overnight. Coating solution was removed and plates were washed with PBS solution. Protein binding sites in coating wells were blocked overnight at 4 °C with 1% skim milk in PBS with 0.5% Tween 20 (PBS-T). Each serum sample was serially diluted with 1% skim milk in PBS-T, added to the well (100 µl each) and incubated for 90 min at 37 °C. The wells were then incubated for one hour at 37 °C with alkaline phosphatase-conjugate goat anti-mouse antibody (Abcam, San Francisco, USA) at a dilution 1:1000. Subsequently, MDA-LDL was detected by chromogenic development using para-nitrophenyl phosphate as the alkaline phosphatase substrate. MDA-LDL was measured in ELISA Reader with absorbance at OD 405 nm λ.

Measurement of visceral fat and body weight

A digital scales (Ohaus CS200. NJ, USA) was used to measure body weight of rats. While for visceral fat measurements, after euthanized using isoflourine anesthesia, epididymal white adipose depots of rats were separated from the epididymis.

The perirenal white adipose depots were then dissected. Finally, dissection was conducted in the intra-abdominal mesenteric adipose depot. Visceral fat mass was determined by weighing the perirenal, mesenteric, and periuterine adipose tissue using a digital scales (Ohaus CS200, NJ, USA).

Measurement of aortic wall thickness

Aortic wall thickness was measured using microscopic histopathology as described previously.³¹ Briefly, after the aorta tissues were embedded and dissected, the aortic sections were deparaffinized by repeated washing with xylene-ethanol and stained with Mayer Hematoxylin and Eosin. The images were captured using a digital camera mounted on a light microscope (Olympus DP71 Microscope Digital Camera, Tokyo, Japan) and the thickness was identified and quantified using image software (Olympus Stream Image Analysis Software, Tokyo, Japan).

Protein profiling of *P. gingivalis* vesicle and its immunoreactivity

Protein profiles of vesicles isolation were analyzed using SDS PAGE electrophoresis. Vesicles were loaded on SDS PAGE gel consisting of 6% separating and 4% stacking gels followed by Coomassie brilliant blue staining. Then, the protein were transferred to nitrocellulose membranes for further analysis using western blot to investigate their reactivity to rat sera after immunization with *P. gingivalis* vesicle. Briefly, the proteins were electrophoretically transferred to nitrocellulose membrane at 4 °C overnight at 40 V and 2 h at 100 V. The membranes were blocked for 1 h at room temperature with 3% gelatin in Tris-buffered saline (500 mmol/L NaCl and 20 mmol/L Tris pH 8.0). The membranes were then incubated with rat sera (1:80 in Tris-buffered saline containing 1% gelatin and 0.05% Tween 20) for 2 h at room temperature. This was followed by 1.5 h incubation at room temperature with alkaline phosphatase-conjugated goat anti mouse immunoglobulin G (IgG) (1:1000) (Abcam, San Francisco, USA).¹⁰

Statistical analysis

ANOVA test was used to analyze the significance of the differences among variables. Post hoc Tukey was used to determine the differences between treatment and control groups. *p*-value less than 0.05 were considered significant. Statistical analyses were performed using Software Statistical Product and Service Solution 18 (SPSS 18, SPSS inc. Chicago, IL, USA).

Results

Protein profile of the *P. gingivalis* vesicles and its immunoreactivity

To identify immunoreactivity of the vesicles of *P. gingivalis*, the vesicles were extracted and the protein profiles were characterized using SDS-PAGE analysis. The electrophoresis showed that the vesicles contained predominant protein

with molecular mass approximately 40 kDa and 28 kDa (Fig. 1A). Western blot showed that the sera from *P. gingivalis* vesicle-immunized rats were significant immunoreactive against both 40 kDa and 28 kDa protein band (Fig. 1B).

MDA-LDL level

To characterize the specific immune response induced by *P. gingivalis* vesicles, circulating MDA-LDL were determined by ELISA. Our results showed that MDA-LDL level of PC, T1, T2, T3 and NC group were $24.53 \pm 7.65 \mu\text{g/ml}$, $22.11 \pm 3.59 \mu\text{g/ml}$, $36.09 \pm 10.28 \mu\text{g/ml}$, $42.74 \pm 15.71 \mu\text{g/ml}$, and $44.73 \pm 7.67 \mu\text{g/ml}$, respectively. There was significant difference among groups ($p = 0.015$). The level of MDA-LDL among rats in T1 group was significantly lower compared to NC group ($22.11 \pm 3.59 \mu\text{g/ml}$ vs. $44.73 \pm 7.67 \mu\text{g/ml}$, $p = 0.037$).

Visceral fat, body weight, and aortic thickness

The mean weight of visceral fats for PC, T1, T2, T3, NC group were $0.98 \pm 0.76 \text{ g}$, $2.66 \pm 0.37 \text{ g}$, $2.80 \pm 0.25 \text{ g}$, $1.93 \pm 0.49 \text{ g}$, and $3.13 \pm 0.84 \text{ g}$, respectively. There was significant difference among groups ($p = 0.001$). However, post hoc analysis suggested no significant difference between T1 and NC group ($p = 0.789$), T2 and NC group ($p = 0.929$) and T3 and NC group ($p = 0.072$) (Table 1). Body weights of animal from PC, T1, T2, T3, and NC group were $67.25 \pm 19.77 \text{ g}$, $69.75 \pm 14.86 \text{ g}$, $100.50 \pm 17.02 \text{ g}$, $89.75 \pm 9.11 \text{ g}$, and $91.00 \pm 13.74 \text{ g}$, respectively. Our analysis using one way ANOVA showed that there was significant difference among groups ($p = 0.031$). However, post hoc analysis suggested no significant difference between NC and T1 ($p = 0.329$) or T2 ($p = 0.901$) or T3 ($p = 1.000$).

As expected, our results showed that the lowest aortic wall was in PC ($26.83 \pm 1.39 \mu\text{m}$) and the highest was in NC ($32.91 \pm 2.28 \mu\text{m}$) and there was significant difference among groups ($p = 0.001$). However, our data showed that the significant difference was observed only between T1 and NC group, with T1 was lower than NC ($29.01 \pm 1.37 \mu\text{m}$ vs. $32.91 \pm 2.28 \mu\text{m}$, $p = 0.016$).

Discussions

Although atherosclerosis-associated diseases are reported to increase,³² up to date, vaccine to prevent

atherosclerosis is not available. Since *P. gingivalis* is associated with inflammation and ox-LDL modification,³³ this species is considered a potential candidate for atherosclerosis vaccine. Our study was conducted to assess the potency of *P. gingivalis* to prevent atherosclerosis in rats model by measuring four atherosclerosis indicators: the level of MDA-LDL, visceral fat, body weight, and aortic thickness.

MDA-LDL plays an important role in the development of atherosclerosis.^{34,35} Several studies had reported that elevated circulating MDA-LDL levels were found in atherosclerosis-associated disease³⁶ including heart disease^{34,37} and peripheral artery disease.³⁸ Our study found that *P. gingivalis* vesicles challenge decreased the level of MDA-LDL. This achieved among rats that were treated with both vesicles and adjuvants, but not with vesicle or adjuvant only (Table 1). This suggested that immunization with *P. gingivalis* vesicles with adjuvant had a protective effect against atherosclerosis, by assessing MD-LDL level, the most important ox-LDL in the pathogenesis of atherosclerosis. The mechanism underlying this association is complex and remains largely undefined. However, this could be explained as follow. MDA-LDL uptake by macrophages would lead to the formation of foam cells and activated foam cells may lead to the upregulation of macrophage receptors, adhesion molecules, the expression of tissue factor, growth factor production, and increase the production of free radicals and inflammatory mediators.^{39,40} These lead to the thickening of blood vessel walls, defined as atherosclerosis.^{39,40} There are four possible mechanisms that bridge between *P. gingivalis* immunization and atherosclerosis. First, Rgp44 on adhesin-hemagglutinin domain of *P. gingivalis* vesicles are shown to have a high immunogenicity,⁴¹ as well as both P1-linear peptide and P2-cyclic peptide on MDA-LDL epitope.⁴² The mimicry of fragment size between Rgp44, P1-linear peptide, and P2-cyclic peptide allegedly raises a cross-immunity.^{41,42} As the result, specific antibodies against Rgp44 on the bacterial vesicles may cross-react with peptides on MDA-LDL.²⁶ Second, immunization with *P. gingivalis* may be able to induce specific IgG serum against atherosclerosis.⁴³ Third, C-reactive protein (CRP) and cytokines may be induced by *P. gingivalis* immunization.⁴⁴ Fourth, *P. gingivalis* immunization may stimulate general activation of B1 cell and interleukin-5 (IL-5) production against atherosclerosis.⁴⁵ Because of these possible mechanisms, MDA-LDL uptake by macrophages and foam cell formation may be




Figure 1 SDS-PAGE and western blot analysis in *P. gingivalis* vesicles. (A) SDS-PAGE illustrated protein profiles in *P. gingivalis* vesicles. (B) Western Blot indicated specific binding of serum IgG from rats immunized with *P. gingivalis* vesicles to the membrane-bound protein component of *P. gingivalis* vesicles at molecular weight 40 kDa and 28 kDa.

Table 1 Summary of measurements in our study.

Parameters	Group (mean \pm SD)				p Among groups	p (T1 vs. NC)	p (T2 vs. NC)	p (T3 vs. NC)	p (PC vs. NC)	
	PC	T1	T2	T3						NC
MDA-LDL ($\mu\text{g/ml}$)	24.53 \pm 7.65	22.11 \pm 3.59	36.09 \pm 10.28	42.74 \pm 15.71	44.73 \pm 7.67	0.015	0.037	0.727	0.998	0.041
Visceral fat (gram)	0.98 \pm 0.76	2.66 \pm 0.37	2.80 \pm 0.25	1.93 \pm 0.49	3.13 \pm 0.84	0.001	0.789	0.929	0.072	0.001
Body weight (gram)	67.25 \pm 19.77	69.75 \pm 14.86	100.50 \pm 17.02	89.75 \pm 9.11	91.00 \pm 13.74	0.031	0.329	0.901	1.000	0.235
Aortic thickness (μm)	26.83 \pm 1.39	29.01 \pm 1.37	30.03 \pm 0.85	31.89 \pm 1.23	32.91 \pm 2.28	0.001	0.016	0.099	0.867	<0.001

Note, SD, standard deviation; MDA-LDL, Malondialdehyde low-density lipoprotein; HFD, high fat diet; PC, Positive control (aquabidest); T1, Treatment 1 (HFD + vesicles + adjuvants); T2, Treatment 2 (HFD + vesicles); T3, Treatment 3 (HFD + adjuvants); NC, Negative control (HFD).

prevented. Moreover, this may also inhibit the adhesion of MDA-LDL in the vascular endothelium. Evidence clearly found that this prevention of foam cells and MDA-LDL accumulation in the intima could ultimately prevent atherosclerosis in vaccinated rats.^{10,39,42} However, further investigation is required to prove the precise mechanism how *P. gingivalis* vesicles decrease the MDA-LDL level.

Currently, a number of studies have focused on atherosclerosis vaccine and most studies assumed that MDA-LDL had a great potency to be a target for atherosclerosis vaccine.^{7–12} Concerning atherosclerosis vaccines with target site at MDA-LDL, our findings confirm and extend the previous studies^{7–12} that immunizations targeting at MDA-LDL have protective effect against atherosclerosis. Moreover, several studies had reported the potency of *P. gingivalis* as an atherosclerosis vaccine using various antigens such as 40-kDa outer membrane protein^{43,44,46,47} and Rgp44⁴⁸; with different route of administration for example subcutaneous,⁴⁸ nasal,^{43,44,46} and oral.⁴⁷ Although their studies had a very complete and specific design, however, most of them used *P. gingivalis* to induce atherosclerosis. This leads to the assumption that the vaccines they designed were only effective for atherosclerosis triggered by *P. gingivalis*. Therefore, the effectiveness of their vaccines against non-infectious atherosclerosis is still questionable. In our present study, we used HFD to induce atherosclerosis. Therefore, it might be assumed that our vaccines had a good effectiveness not only against *P. gingivalis*-induced atherosclerosis but also non-infectious atherosclerosis. Furthermore, they used only negative controls. Our present study did not only use negative control but also positive control. Therefore, the best and worst data limits could be known. Of those studies, our study is most similar to study by Turunen et al.⁴⁵ They evaluated MDA-LDL immunization in mice challenged with *P. gingivalis* and the levels of IgG, IgM, IL-5, IL-10, and interferon- γ (IFN- γ) were measured. They showed that MDA-LDL-immunized mice had elevated IgM and IgG levels to MDA-LDL and increased IL-5 production compared to controls. Overall, they found that MDA-LDL immunization in mice induced with *P. gingivalis* challenge had significantly reduced aortic plaque formation compared to mice without immunization. However, reduction of plaque formation in MDA-LDL-immunized mice was not significant compared to mice that given HFD only, although there were some declines in aortic lipid deposition. Furthermore, the use of LDL modification as atheroprotective immunogen seems to be impractical for generalized use.⁴⁹ On the other hand, whole bacteria utilization, despite its effectiveness to elicit antibody response against disease, is still controversial following some studies^{50–53} that linked its infection to accelerate several side effects.

Our results found that Freund's adjuvants, both CFA and IFA alone, had no protective effects against atherosclerosis. Previous studies had shown the protective effect of adjuvants in atherosclerosis.^{12,54–56} The mechanism of adjuvants as atheroprotective includes their capacity to increase IgG and IgM against MDA-LDL.^{55,56} Our results were contrast with those previous studies. Further studies are required to elucidate this difference. However, atheroprotective effect of adjuvants is a complex involving several factors. A study revealed that atheroprotective

effect of adjuvants is CD4-dependent.¹² Therefore, this may explain our results, adjuvants alone may not confer protection against atherosclerosis, and the combination of adjuvants and *P. gingivalis* vesicles may provide protection against atherosclerosis as reported in our study. However, this reason is not a final. In the near future, we expect there will be studies investigating how the precise mechanism of adjuvants in atherosclerosis.

We also evaluated the effect of *P. gingivalis* vesicles challenge on aortic wall thickness. Our data indicates that administration of vesicles with adjuvants decrease aortic wall thickness significantly compared to negative control group. This could be because of cross reaction response caused by *P. gingivalis* immunization. Foam cells accumulation caused by MDA-LDL uptake by macrophages is the basic mechanism for aortic wall thickness and atherosclerosis.³⁹ Therefore, prevention of foam cell accumulation stimulated by *P. gingivalis* immunization²⁶ has the important role to prevent the thickening of aortic wall. Our study found that *P. gingivalis* vesicles did not associate with reduction of visceral fat and body weight. One of the plausible reasons is visceral fat and obesity indeed have been linked to atherosclerosis risk factors, however they are chronic and prolonged process.^{57,58} Therefore, with a short time period of our study, it is understandable that *P. gingivalis* immunization has no effect on visceral fat and body weight of rats.

Our study demonstrated a good efficacy of *P. gingivalis* as an atherosclerosis vaccine. Our study was consistent to previous studies concerning *P. gingivalis* efficacy as an atherosclerosis vaccine in animal models. Further investigation with more specific design or involving genetic approach or in higher level of trials needs to be performed. Moreover, to evaluate the response of society regarding atherosclerosis vaccines, the acceptance and or willingness to pay studies may be needed.

There were several limitations in our study. We did not assess other variable that likely to have effect on atherosclerosis such as the level of triglyceride, cholesterol, fasting blood sugar, CRP, and LDL. In addition, the possibility of a false negative remains due to the small number of tested animals.

Conclusion

Our data suggest that *P. gingivalis* vesicles have protective effect in preventing atherosclerosis by reducing the level of MDA-LDL and aortic wall thickness in animal model. However, further studies are required to elucidate the mechanisms of these effects.

Author contributions

Designed the experiments = AIM. Performed the experiments = AIM Analyzed the data = AIM, JKF, TH. Contributed reagents/material/analysis tools = AIM. Wrote the manuscript = AIM, JKF, HH, TH. Reference collection and data management = AIM, JKF, HH, TH. Statistical analyses and paper writing = AIM, JKF, HH, TH. Revised manuscript = SRP, EW, MSR, KM, BSP, YP.

Conflict of interest

The authors declared that there is no conflict of interest regarding the publication of this paper.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.artres.2018.05.008>.

References

1. Chatzidimitriou D, Kirmizis D, Gavrilaki E, Chatzidimitriou M, Malisiovas N. Atherosclerosis and infection: is the jury still not in? *Future Microbiol* 2012;**7**(10):1217–30.
2. Fajar JK. The β fibrinogen gene G-455A polymorphism in Asian subjects with coronary heart disease: a meta analysis. *Egypt J Med Hum Genet* 2017;**18**:19–28.
3. World Health Organization. *Cardiovascular diseases (CVDs)*. Geneva: World Health Organization; 2017.
4. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Atherosclerosis* 2016;**253**:281–344.
5. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. *N Engl J Med* 2015;**372**(14):1333–41.
6. Negi S, Anand A. Atherosclerotic coronary heart disease-epidemiology, classification and management. *Cardiovasc Hematol Disord Drug Targets* 2010;**10**(4):257–61.
7. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. *Proc Natl Acad Sci USA* 1995;**92**:821–5.
8. Freigang S, Horkko S, Miller E, Witztum JL, Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neopeptides. *Arterioscler Thromb Vasc Biol* 1998;**18**:1972–82.
9. George J, Afek A, Gilburd B, Levkovitz H, Shaish A, Goldberg I, et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. *Atherosclerosis* 1998;**138**:147–52.
10. Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. *Arterioscler Thromb Vasc Biol* 2001;**21**:108–14.
11. Chyu KY, Reyes OS, Zhao X, Yano J, Dimayuga P, Nilsson J, et al. Timing affects the efficacy of LDL immunization on atherosclerotic lesions in apoE (-/-) mice. *Atherosclerosis* 2004;**176**:27–35.
12. Zhou X, Robertson AK, Rudling M, Parini P, Hansson GK. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. *Circ Res* 2005;**96**:427–34.
13. Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, Cercek B, et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. *Arterioscler Thromb Vasc Biol* 1996;**16**:1074–9.

14. Habets KL, van Puijvelde GH, van Duivenvoorde LM, van Wanrooij EJ, de Vos P, Tervaert JW, et al. Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. *Cardiovasc Res* 2010;**85**:622–30.
15. Zhang Y, Xiong Q, Hu X, Sun Y, Tan X, Zhang H, et al. A novel atherogenic epitope from *Mycobacterium tuberculosis* heat shock protein 65 enhances atherosclerosis in rabbit and LDL receptor-deficient mice. *Heart Vessels* 2012;**27**:411–8.
16. Fredrikson GN, Björkbacka H, Soderberg I, Ljungcrantz I, Nilsson J. Treatment with apoB peptide vaccines inhibits atherosclerosis in human apoB-100 transgenic mice without inducing an increase in peptide-specific antibodies. *J Intern Med* 2008;**264**:563–70.
17. Klingenberg R, Lebens M, Hermansson A, Fredrikson GN, Strodthoff D, Rudling M, et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. *Arterioscler Thromb Vasc Biol* 2010;**30**:946–52.
18. Wigren M, Kolbus D, Duner P, Ljungcrantz I, Söderberg I, Björkbacka H, et al. Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. *J Intern Med* 2010;**269**:546–56.
19. Chyu KY, Zhao X, Dimayuga PC, Zhou J, Li X, Yano J, et al. CD8⁺ T cells mediate the athero-protective effect of immunization with an apoB-100 peptide. *PLoS One* 2012;**7**:e30780.
20. Moriyama K, Takahashi E. Evaluation of malondialdehyde low-density lipoprotein stratified by low-density lipoprotein cholesterol. *Clin Lab* 2017;**63**(7):1179–86.
21. Binder CJ, Hökkö S, Dewan A, Chang MK, Kieu EP, Goodyear CS, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between *Streptococcus pneumoniae* and oxidized LDL. *Nat Med* 2003;**9**(6):736–43.
22. Winarsih S, Yudhinata RBN, Zaka MP, Luthfia TS, Tamara F, Indra AM. Atherosclerosis vaccine using bacteria *Salmonella typhimurium* on rat models. *Br J Med Med Res* 2014;**4**(36):5729–40.
23. Lavallée P, Perchaud V, Gautier-Bertrand M, Grabli D, Amarenco P. Association between influenza vaccination and reduced risk of brain infarction. *Stroke* 2002;**33**(2):513–8.
24. Ren S, Hure A, Peel R, D'Este C, Abhayaratna W, Tonkin A, et al., AUSPICE Study Group. Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: the Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). *Am Heart J* 2016;**177**: 58–56.
25. Hussain M, Stover CM, Dupont AP. *Gingivitis* in periodontal disease and atherosclerosis – scenes of action for antimicrobial peptides and complement. *Front Immunol* 2015;**6**:45.
26. Turunen SP, Kumm O, Harila K, Veneskoski M, Soliymani R, Baumann M, et al. Recognition of *Porphyromonas gingivalis* gingipain epitopes by natural IgM binding to malondialdehyde modified low-density lipoprotein. *PLoS One* 2012;**7**(4):e34910.
27. Frank SA. *Immunology and evolution of infectious disease*. Princeton: Princeton University Press; 2002.
28. Grenier D, Mayrand D. Functional characterization of extracellular vesicles produced by *Bacteroides gingivalis*. *Infect Immun* 1987;**55**(1):111–7.
29. Raja B, Saravanakumar M, Sathya G. Veratric acid ameliorates hyperlipidemia and oxidative stress in Wistar rats fed an atherogenic diet. *Mol Cell Biochem* 2012;**366**(1–2):21–30.
30. Nakao R, Hasegawa H, Ochiai K, Takashiba S, Ainai A, Ohnishi M, et al. Outer membrane vesicles of *Porphyromonas gingivalis* elicit a mucosal immune response. *PLoS One* 2011;**6**(10):e26163.
31. Venegas-Pino DE, Banko N, Khan MI, Shi Y, Werstuck GH. Quantitative analysis and characterization of atherosclerotic lesions in the murine aortic sinus. *J Vis Exp* 2013;**82**:50933.
32. Arbab-Zadeh A, Fuster V. The myth of the “vulnerable plaque”: transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. *J Am Coll Cardiol* 2015;**65**(8):846–55.
33. Kurita-Ochiai T, Yamamoto M. Periodontal pathogens and atherosclerosis: implications of inflammation and oxidative modification of LDL. *Biomed Res Int* 2014;**2014**:595981.
34. Amaki T, Suzuki T, Nakamura F, Hayashi D, Imai Y, Morita H, et al. Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease. *Heart* 2004;**90**(10):1211–3.
35. Suzuki H, Sasaki T, Kumagai T, Sakaguchi S, Nagata K. Malondialdehyde-modified low density lipoprotein (MDA-LDL)-induced cell growth was suppressed by polycyclic aromatic hydrocarbons (PAHs). *J Toxicol Sci* 2010;**35**(2):137–47.
36. Viigimaa M, Abina J, Zemtsovskaya G, Tikhaze A, Konovalova G, Kumskova E, et al. Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis. *Blood Press* 2010;**19**(3):164–8.
37. Tanaga K, Bujo H, Inoue M, Mikami K, Kotani K, Takahashi K, et al. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. *Arterioscler Thromb Vasc Biol* 2002;**22**(4):662–6.
38. Takamura TA, Tsuchiya T, Oda M, Watanabe M, Saito R, Sato-Ishida R, et al. Circulating malondialdehyde-modified low-density lipoprotein (MDA-LDL) as a novel predictor of clinical outcome after endovascular therapy in patients with peripheral artery disease (PAD). *Atherosclerosis* 2017;**263**:192–7.
39. Kearney JF. Immune recognition of OxLDL in atherosclerosis. *J Clin Invest* 2000;**105**(12):1683–5.
40. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. *N Engl J Med* 2005;**353**(1):46–57.
41. Veith PD, Talbo GH, Slakeski N, Dashper SG, Moore C, Paolini RA, et al. Major outer membrane proteins and proteolytic processing of RgpA and Kgp of *Porphyromonas gingivalis* W50. *Biochem J* 2002;**363**(Pt. 1):105–15.
42. Amir S, Hartvigsen K, Gonen A, Leibundgut G, Que X, Jensen-Jarolim E, et al. Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. *J Lipid Res* 2012;**53**(7):1316–26.
43. Koizumi Y, Kurita-Ochiai T, Oguchi S, Yamamoto M. Nasal immunization with *Porphyromonas gingivalis* outer membrane protein decreases *P. gingivalis*-induced atherosclerosis and inflammation in spontaneously hyperlipidemic mice. *Infect Immun* 2008;**76**(7):2958–65.
44. Fukasawa A, Kurita-Ochiai T, Hashizume T, Kobayashi R, Akimoto Y, Yamamoto M. Intranasal immunization with *Porphyromonas gingivalis* outer membrane protein inhibits *P. gingivalis* – induced atherosclerosis in C57BL/6 mice fed a high-fat diet. *Int J Oral Med Sci* 2012;**10**(4):362–71.
45. Turunen SP, Kumm O, Wang C, Harila K, Mattila R, Sahlman M, et al. Immunization with malondialdehyde-modified low-density lipoprotein (LDL) reduces atherosclerosis in LDL receptor-deficient mice challenged with *Porphyromonas gingivalis*. *Innate Immun* 2015;**21**(4):370–85.
46. Koizumi Y, Kurita-Ochiai T, Oguchi S, Yamamoto M. Nasal immunization with a 40-kDa outer membrane protein of *Porphyromonas gingivalis* inhibits atherosclerotic plaque accumulation caused by oral *P. gingivalis* infection. *Int J Oral Med Sci* 2008;**6**(3):150–8.
47. Takeuchi T, Hashizume-Takizawa T, Kobayashi R. Oral immunization with *Porphyromonas gingivalis* outer membrane protein and CpG oligodeoxynucleotides attenuates *P. gingivalis*-accelerated atherosclerosis and inflammation. *J Oral Biosciences* 2017;**59**(4):224–30.

48. Kyrklund M, Kumm O, Kankaanpää J, Akhi R, Nissinen A, Turunen SP, et al. Immunization with gingipain A hemagglutinin domain of *Porphyromonas gingivalis* induces IgM antibodies binding to malondialdehyde-acetaldehyde modified low-density lipoprotein. *PLoS One* 2018;**13**(1):e0191216.
49. Gonen A, Hansen LF, Turner WW, Montano EN, Que X, Rafia A, et al. Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine. *J Lipid Res* 2014;**55**:2137–55.
50. Baker JP. The pertussis vaccine controversy in Great Britain, 1974–1986. *Vaccine* 2003;**21**(25–26):4003–10.
51. Bronfin DR. Childhood immunization controversies: what are parents asking? *Ochsner J* 2008;**8**(3):151–6.
52. Donnelly S, Loscher CE, Lynch MA, Mills KH. Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: evidence of a role for toxin-induced interleukin-1beta in a new murine model for analysis of neuronal side effects of vaccination. *Infect Immun* 2001;**69**(7):4217–23.
53. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. *N Engl J Med* 1996;**334**(6):341–8.
54. Hansen PR, Chew M, Zhou J, Daugherty A, Heegaard N, Jensen P, et al. Freund's adjuvant alone is antiatherogenic in apoE-deficient mice and specific immunization against TNFalpha confers no additional benefit. *Atherosclerosis* 2001;**158**(1):87–94.
55. Shi GP. Immunomodulation of vascular diseases: atherosclerosis and autoimmunity. *Eur J Vasc Endovasc Surg* 2010;**39**(4):485–94.
56. Khallou-Laschet J, Tupin E, Caligiuri G, Poirier B, Thieblemont N, Gaston AT, et al. Atheroprotective effect of adjuvants in apolipoprotein E knockout mice. *Atherosclerosis* 2006;**184**(2):330–41.
57. Yamauchi T, Kuno T, Takada H, Nagura Y, Kanmatsuse K, Takahashi S. The impact of visceral fat on multiple risk factors and carotid atherosclerosis in chronic haemodialysis patients. *Nephrol Dial Transplant* 2003;**18**(9):1842–7.
58. Shively CA, Register TC, Clarkson TB. Social stress, visceral obesity, and coronary artery atherosclerosis: product of a primate adaptation. *Am J Primatol* 2009;**71**(9):742–51.